NIAID-sponsored trial of experimental Chikungunya vaccine begins

(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial of an experimental vaccine to prevent infection with chikungunya virus is now enrolling healthy adult volunteers at sites in the United States.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news

Related Links:

We describe the unexpected binding of S-layer to cells devoid of DC-SIGN but also confirm that the presence of DC-SIGN was essential for S-layer’s antiviral activity. S-layer protein exerted its antiviral effect with different kinetics than mannan, a known viral inhibitor that also acts on DC-SIGN (Yu et al., 2017). Together our results suggest that inhibition of viral entry by S-layer occurs via a novel S-layer/DC-SIGN interaction. Materials and Methods Isolation of S-Layer Proteins S-layer proteins were extracted from overnight cultures of L. acidophilus ATCC 4356 cells grown in MRS medium at 37°C by using 6...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Tapas Kumar Nayak1†, Prabhudutta Mamidi2, Subhransu Sekhar Sahoo1, P. Sanjai Kumar1, Chandan Mahish1, Sanchari Chatterjee2, Bharat Bhusan Subudhi3, Soma Chattopadhyay2 and Subhasis Chattopadhyay1* 1School of Biological Sciences, National Institute of Science Education and Research, HBNI, Bhubaneswar, India2Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, India3School of Pharmaceutical Sciences, Siksha O Anusandhan University, Bhubaneswar, India Chikungunya virus (CHIKV), a mosquito-borne Alphavirus, is endemic in different parts of the globe. The host macrophages are identified as the maj...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion The results obtained from this research shows, in general, the fragility in the social and political infrastructure necessary to improve the living conditions of populations, particularly those that depend on family agriculture in drought prone areas. The conditions of social, economic and environmental vulnerabilities presented in the region can be amplified by the drought process, and can aggravate the impacts resulting drought events, thus disadvantaging the population of this region, as shown in the Fig. 1. The general perception of the interviewees of the health sector shows an agreement with what is found...
Source: PLOS Currents Disasters - Category: International Medicine & Public Health Authors: Source Type: research
Conclusions Epitopes reported in this study showed promiscuity, antigenicity as well as good binding affinity for the HLA classes. These epitopes will provide the baseline for development of efficacious vaccine for CHIKV.
Source: Asian Pacific Journal of Tropical Medicine - Category: Tropical Medicine Source Type: research
A phase 1 and 2 clinical trial of anexperimental vaccineagainst the viral disease chikungunya has begun enrolling a planned 180 healthy adult volunteers aged 18 to 45 years with funding by the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine, known as MV-CHIKV, is a recombinant live-attenuated measles vaccine virus expressing chikungunya proteins that induce antibody production.
Source: JAMA - Category: General Medicine Source Type: research
AbstractChikungunya virus (CHIKV) has been involved in epidemics in African and Asian subcontinents and, of late, has transcended to affect the Americas.Aedes aegypti andAedes albopictus are the major vectors for CHIKV infection, which results in dissemination of virus to various vital organs. Entry of virus into these tissues causes infiltration of innate immune cells, monocytes, macrophages, neutrophils, natural killer cells, and adaptive immune cells. Macrophages bearing the replicating virus, in turn, secrete pro-inflammatory cytokines IL-1 β, TNF-α, and IL-17. Together, this pro-inflammatory milieu induces ...
Source: Current Allergy and Asthma Reports - Category: Allergy & Immunology Source Type: research
Editor’s Note: This post reflects on a speech on pandemic preparedness Dr. Fauci gave on January 10, 2017 in Washington, DC, hosted by  The Center for Global Health Science and Security at Georgetown University Medical Center, the Harvard Global Health Institute, and Health Affairs. One of the most important challenges facing the new Administration is preparedness for the pandemic outbreak of an infectious disease. Infectious diseases will continue to pose a significant threat to public health and the economies of countries worldwide. The U.S. government will need to continue its investment to combat these ...
Source: Health Affairs Blog - Category: Health Management Authors: Tags: Featured Global Health Policy Ebola HIV/AIDS NIH pandemic preparedness Zika Source Type: blogs
Since the early 2000's, chikungunya has been considered to be a rapidly expanding, re-emerging, tropical disease. This led the National Institute of Allergy and Infectious Diseases (NIAID) together with the World Health Organization (WHO) to organize an expert consultation in June 2015. At the meeting, the major socioeconomic impact and the large public health burden, due to a high rate of debilitating, chronic arthritis and other co-morbidities, were highlighted. Some evidence was also found that chikungunya is likely to remain a difficult infection to prevent or control, even when vaccines and effective treatments become available [1].
Source: Travel Medicine and Infectious Disease - Category: Infectious Diseases Authors: Tags: Editorial Source Type: research
Zika virus’ status as a global health threat may officially be over, but the disease’s impact is far from contained.  The World Health Organization decided in November to end its designation of Zika virus as a public health emergency, but that doesn’t mean that Zika virus has disappeared, explained Dr. Carlos Pardo-Villamizar, a clinical neurologist with an expertise in infectious disorders at Johns Hopkins Medicine. Alongside pressing concerns about how to prevent a resurgence of the disease, health care systems in Brazil and other countries that saw births of babies infected with the disease in ute...
Source: Science - The Huffington Post - Category: Science Source Type: news
Discovered in 1953, chikungunya virus (CHIKV) circulated in Africa and Southeast Asia, with periodic outbreaks, for many years. Highly efficient transmission following a genetic mutation of the virus in 2005 caused its global spread. Associated with significant morbidity, CHIKV creates a large public health burden, and despite various efforts, there are currently no licensed vaccines nor specific treatments. To garner a better understanding of the virus, identify gaps in knowledge, and guide the development of more-effective interventions, the World Health Organization and National Institute of Allergy and Infectious Disea...
Source: The Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: CHIKUNGUNYA Source Type: research
More News: Allergy | Allergy & Immunology | Chikungunya | Clinical Trials | Infectious Diseases | Vaccines